Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia.

Joachimsen L, Böhringer D, Gross NJ, Reich M, Stifter J, Reinhard T, Lagrèze WA.

Ophthalmol Ther. 2019 Sep;8(3):427-433. doi: 10.1007/s40123-019-0194-6. Epub 2019 Jun 12.

2.

[Amblyopia and refractive error].

Joachimsen L, Gross NJ, Lagrèze WA.

Klin Monbl Augenheilkd. 2018 Aug;235(8):945-954. doi: 10.1055/a-0639-3421. Epub 2018 Aug 10. German.

PMID:
30096724
3.

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.

Tashkin DP, Gross NJ.

Int J Chron Obstruct Pulmon Dis. 2018 Jun 12;13:1873-1888. doi: 10.2147/COPD.S162646. eCollection 2018. Review.

4.

Visual field defects following different resective procedures for mesiotemporal lobe epilepsy.

Schmeiser B, Daniel M, Kogias E, Böhringer D, Egger K, Yang S, Foit NA, Schulze-Bonhage A, Steinhoff BJ, Zentner J, Lagrèze WA, Gross NJ.

Epilepsy Behav. 2017 Nov;76:39-45. doi: 10.1016/j.yebeh.2017.08.037. Epub 2017 Sep 24.

PMID:
28954709
5.

Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.

Gerardi DA, Gross NJ.

Chronic Obstr Pulm Dis. 2017 Jan 5;4(1):1-3. doi: 10.15326/jcopdf.4.1.2016.0175. No abstract available.

6.

New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.

Gross NJ, Barnes PJ.

Am J Respir Crit Care Med. 2017 Jan 15;195(2):159-166. doi: 10.1164/rccm.201610-2074PP. No abstract available.

PMID:
27922751
7.

[Induced Incomitance of one Muscle Strabismus Surgery in Comparison to Unilateral Recess-Resect Procedures].

Gross NJ, Link H, Biermann J, Kiechle M, Lagrèze WA.

Klin Monbl Augenheilkd. 2015 Oct;232(10):1174-7. doi: 10.1055/s-0041-104776. Epub 2015 Oct 29. German.

PMID:
26512848
8.

Terson's Syndrome: Diagnostic Comparison of Ocular Sonography and CT.

Bäuerle J, Gross NJ, Egger K, Neubauer J, Niesen WD, Buttler KJ, Lagrèze WA, Reinhard M.

J Neuroimaging. 2016 Mar-Apr;26(2):247-52. doi: 10.1111/jon.12285. Epub 2015 Aug 6.

PMID:
26250688
9.

[Perforating keratoplasty versus Descemet stripping automated endothelial keratoplasty in the partner eye: Functional results and patient satisfaction].

Gross NJ, Böhringer D, Maier P, Reinhard T.

Ophthalmologe. 2015 Oct;112(10):848-53. doi: 10.1007/s00347-015-0010-1. German.

PMID:
25943048
10.

Marked dissociation of photopic and mesopic contrast sensitivity even in normal observers.

Hertenstein H, Bach M, Gross NJ, Beisse F.

Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):373-84. doi: 10.1007/s00417-015-3020-4. Epub 2015 Apr 29.

PMID:
25921390
11.

[Prevalence of glaucoma in obstructive sleep apnea].

Gross NJ, Funk J, Pache M, van der List M, Laubmann-Volz A, Sorichter S, Lagrèze WA.

Ophthalmologe. 2015 Jul;112(7):580-4. doi: 10.1007/s00347-014-3146-5. German.

PMID:
25585796
12.

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Blanchette CM, Gross NJ, Altman P.

Am Health Drug Benefits. 2014 Apr;7(2):98-106. Review.

13.

The COPD pipeline XXIV.

Gross NJ.

COPD. 2013 Oct;10(5):625-7. doi: 10.3109/15412555.2013.832093. No abstract available.

PMID:
24040908
14.

The COPD pipeline XXII.

Gross NJ.

COPD. 2013 Jun;10(3):390-2. doi: 10.3109/15412555.2013.795422. No abstract available.

PMID:
23713599
15.

Safety and tolerability of inhalational anticholinergics in COPD.

Sharafkhaneh A, Majid H, Gross NJ.

Drug Healthc Patient Saf. 2013;5:49-55. doi: 10.2147/DHPS.S7771. Epub 2013 Mar 8.

16.

Novel antiinflammatory therapies for COPD.

Gross NJ.

Chest. 2012 Nov;142(5):1300-1307. doi: 10.1378/chest.11-2766. Review.

PMID:
23131938
17.

The COPD pipeline XVIII.

Gross NJ.

COPD. 2012 Aug;9(5):571-3. doi: 10.3109/15412555.2012.718927. Epub 2012 Sep 4. No abstract available.

PMID:
22946846
18.

The COPD Pipeline XIV.

Gross NJ.

COPD. 2012 Feb;9(1):81-3. doi: 10.3109/15412555.2012.646587. No abstract available.

PMID:
22292600
19.

The COPD Pipeline XIII.

Gross NJ.

COPD. 2011 Dec;8(6):464-5. doi: 10.3109/15412555.2011.628597. No abstract available.

PMID:
22149408
20.

The COPD Pipeline XII.

Gross NJ, Hanania NA.

COPD. 2011 Oct;8(5):387-91. doi: 10.3109/15412555.2011.613704. Epub 2011 Sep 9. Review. No abstract available.

PMID:
21905763
21.

The COPD Pipeline XI.

Gross NJ.

COPD. 2011 Aug;8(4):320-2. doi: 10.3109/15412555.2011.596445. Epub 2011 Jul 5. No abstract available.

PMID:
21728806
22.

The COPD pipeline x.

Gross NJ.

COPD. 2011 Jun;8(3):244-7. doi: 10.3109/15412555.2011.576887. Epub 2011 May 11. No abstract available.

PMID:
21561234
23.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.

Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.

Respir Res. 2011 Apr 26;12:55. doi: 10.1186/1465-9921-12-55.

24.

The COPD Pipeline IX.

Gross NJ.

COPD. 2011 Apr;8(2):136-8. doi: 10.3109/15412555.2011.559377. No abstract available.

PMID:
21495841
25.

The COPD pipeline VIII.

Gross NJ.

COPD. 2011 Feb;8(1):52-4. doi: 10.3109/15412555.2011.541142. No abstract available.

PMID:
21299478
26.

The COPD pipeline VII.

Gross NJ.

COPD. 2010 Dec;7(6):438-40. doi: 10.3109/15412555.2010.527736. No abstract available.

PMID:
21166632
27.

The COPD pipeline VI.

Gross NJ.

COPD. 2010 Oct;7(5):383-5. doi: 10.3109/15412555.2010.512505. Review. No abstract available.

PMID:
20854054
28.

Nebulized formoterol: a review of clinical efficacy and safety in COPD.

Gross NJ, Donohue JF.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:223-32. Review.

29.

The COPD pipeline IV.

Gross NJ.

COPD. 2010 Jun;7(3):229-31. doi: 10.3109/15412555.2010.485494. Review. No abstract available.

PMID:
20486822
30.

The COPD pipeline.

Gross NJ.

COPD. 2010 Apr;7(2):154-6. doi: 10.3109/15412551003719637. No abstract available.

PMID:
20397816
31.

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

Gross NJ, Giembycz MA, Rennard SI.

COPD. 2010 Apr;7(2):141-53. doi: 10.3109/15412551003758304. Review.

PMID:
20397815
32.

Managing acute exacerbations of COPD: a scorecard.

Gross NJ.

COPD. 2010 Apr;7(2):81-2. doi: 10.3109/15412551003719587. No abstract available.

PMID:
20397806
33.

The COPD Pipeline II.

Gross NJ.

COPD. 2010 Feb;7(1):76-8. doi: 10.3109/15412550903501244. Review. No abstract available.

PMID:
20214467
34.

The COPD Pipeline.

Gross NJ.

COPD. 2009 Dec;6(6):488-9. doi: 10.3109/15412550903368417. No abstract available.

PMID:
19938973
35.

Alternative mechanisms for tiotropium.

Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, Nadel JA, Pfeifer M, Racké K, Rabe KF, Rubin BK, Welte T, Wessler I.

Pulm Pharmacol Ther. 2009 Dec;22(6):533-42. doi: 10.1016/j.pupt.2009.06.002. Epub 2009 Jul 25. Review.

PMID:
19635581
36.

How much did biases in the study of chronic obstructive pulmonary disease medications and mortality affect the outcome?

Gross NJ.

Ann Intern Med. 2009 Mar 17;150(6):426; author reply 426-7. No abstract available.

PMID:
19293081
37.

Chronic obstructive pulmonary disease: an evidence-based approach to treatment with a focus on anticholinergic bronchodilation.

Gross NJ.

Mayo Clin Proc. 2008 Nov;83(11):1241-50. doi: 10.4065/83.11.1241. Review.

PMID:
18990323
38.

Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro.

Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT.

FEBS Lett. 2008 Sep 3;582(20):3097-102. doi: 10.1016/j.febslet.2008.08.005. Epub 2008 Aug 12.

39.

Nebulized formoterol fumarate: Dose selection and pharmacokinetics.

Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M.

Pulm Pharmacol Ther. 2008 Oct;21(5):818-23. doi: 10.1016/j.pupt.2008.07.002. Epub 2008 Jul 8.

PMID:
18655841
40.

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.

Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group.

Respir Med. 2008 Feb;102(2):189-97.

41.

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.

Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group.

Clin Ther. 2007 Oct;29(10):2167-78. Erratum in: Clin Ther. 2009 Apr;31(4):920.

PMID:
18042473
42.

Albuterol inhalers.

Gross NJ.

N Engl J Med. 2007 Jun 28;356(26):2749; author reply 2749. No abstract available.

PMID:
17596614
43.

Outcome measures for COPD treatments: a critical evaluation.

Gross NJ.

COPD. 2004 Apr;1(1):41-57. Review. No abstract available.

PMID:
16997738
44.

Anticholinergic agents in asthma and COPD.

Gross NJ.

Eur J Pharmacol. 2006 Mar 8;533(1-3):36-9. Epub 2006 Feb 20. Review.

PMID:
16488410
45.

Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful?

Gross NJ.

Proc Am Thorac Soc. 2005;2(4):267-71; discussion 290-1. Review.

PMID:
16267347
46.

Tiotropium bromide.

Gross NJ.

Chest. 2004 Dec;126(6):1946-53. Review.

PMID:
15596697
47.
48.

Outcome measurements in COPD: are we schizophrenic?

Gross NJ.

Chest. 2003 May;123(5):1325-7. No abstract available.

PMID:
12740238
49.

The GOLD standard for chronic obstructive pulmonary disease.

Gross NJ.

Am J Respir Crit Care Med. 2001 Apr;163(5):1047-8. No abstract available.

PMID:
11316631
50.

Extrapulmonary effects of chronic obstructive pulmonary disease.

Gross NJ.

Curr Opin Pulm Med. 2001 Mar;7(2):84-92. Review.

PMID:
11224729

Supplemental Content

Loading ...
Support Center